Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 96Leukemia 90Myelodysplastic Syndromes 83Precursor Cell Lymphoblastic Leukemia-Lymphoma 71Lymphoma, Non-Hodgkin 62Lymphoma 60Multiple Myeloma 53Hodgkin Disease 48Leukemia, Lymphocytic, Chronic, B-Cell 46Myeloproliferative Disorders 41Leukemia, Myeloid, Chronic-Phase 41Leukemia, Myeloid, Accelerated Phase 37Congenital Abnormalities 37Lymphoma, Large B-Cell, Diffuse 35Neoplasms, Plasma Cell 34Lymphoma, Follicular 34Leukemia, Myelomonocytic, Chronic 34Burkitt Lymphoma 33Anemia, Refractory, with Excess of Blasts 32Lymphoma, Mantle-Cell 31Lymphoma, B-Cell, Marginal Zone 29Leukemia, Myelogenous, Chronic, BCR-ABL Positive 29Lymphoma, Large-Cell, Immunoblastic 28Blast Crisis 26Myelodysplastic-Myeloproliferative Diseases 25Recurrence 24Primary Myelofibrosis 24Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 24Hematologic Neoplasms 24Dendritic Cell Sarcoma, Interdigitating 22

Interventions

pomalidomide 2daratumumab 2Dexamethasone 2ixazomib 1dexamethasone acetate 1dexamethasone 21-phosphate 1cc-486 1auricularum 1Radiotherapy 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1Melphalan 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Gemcitabine 1Drug Combinations 1Calcium Dobesilate 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Plasmacytoma × Busulfan × Clear all
NCT02506959 2025-03-18

Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

M.D. Anderson Cancer Center

Phase 2 Completed
83 enrolled 11 charts
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡